Childhood obesity is a formidable public health challenge in the US, posing a risk of various downstream health issues for ...

Early results from Wave's ongoing DMD Phase II trial saw a decline in muscle necrosis and inflammation in the trial ...

Acumen Pharmaceuticals has concluded enrolment for the Phase II ALTITUDE-AD trial of sabirnetug for treating patients with ...

Despite missing its primary endpoint, Equillium is pushing ahead with itolizumab citing its complete response by day 99.

Epicrispr has raised $68m in the initial close of its Series B financing round to commence the clinical trial of EPI-321 for ...

Lipocine has announced the commencement of a Phase III clinical trial of LPCN 1154, being developed for postpartum depression ...

While Cassava is stopping investigations into simufilam in Alzheimer’s disease, the therapy is now being evaluated in ...

KalVista Pharmaceuticals has finished enrolling subjects in its KONFIDENT-KID trial of sebetralstat for hereditary angioedema ...

The randomised trial saw more than half of patients dosed with Sunosi achieving clinical response to the therapy used to ...

Helicore Biopharma has dosed the first subject in the randomised first-in-human Phase I trial of HCR-188 to treat obesity.

Entrada Therapeutics has secured authorisation from the UK MHRA to commence Phase I/II trial of ENTR-601-45 for treating DMD.

Unity Biotechnology has reported outcomes from its randomised Phase IIb ASPIRE study of intravitreal UBX1325 for diabetic ...